in 149 countries, including 5,000 in France.
5 major R&D areas
cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.
100 Million patients
treated daily with Servier medicinal products and generics.
15 international centers of clinical development
and 3 research centers.
16 chemical & pharmaceutical production sites
producing chemicals and pharmaceuticals worldwide.
4,2 billion euros turnover
comprising 2.9 billion euros for Servier and 1.2 billion euros for generics.
25 % of turnover from Servier drugs is invested in R&D
No. 2 pharmaceutical company in france
no. 30 in the world; 3 research centres including 2 in France.
No.1 in cardiology in France
no. 2 in Europe, No. 8 in the world.
2nd leading preferred partner for research centers conducting clinical trials
According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies
Servier earned the highest score of A3++
As in previous years, this high score represents excellence in honoring financial commitments.
Participation reached 36.6% of the trade balance surplus in france
In pharmaceuticals and fine chemicals, amounting to 1.4 billion euros.